For those patients who were undergoing bilateral simultaneous treatment (n = 20), the eye with the worse visual acuity was included in the audit. Where the vision was equal in the two eyes, the right or left eye was randomly chosen for further analysis.
Results

Patient characteristics
Two hundred and eighty-four patients undergoing the first pametinal photocoagulation in one eye were recruited into the audit. Their mean age was 54.8 years, range 17-85 years; 42.1% were female, and 57.9% were Mode of detection of the retinopathy that le� to referral to the ophthalmology outpatient clinic, for those patients In whom prolif erative retinopathy was present at the first ophthalmology outpahent visit (n = 94). In this context, systematic screening refers to the detection of retinopathy as a result of at least annual, planned, dilated fundal examination by an optometrist or doctor. A chance finding refers to the detection of the pathology in a patient who did not undergo systematic screening as defined above, and who did not present symptomatically. presented symptomatically, and the retinopathy was detected by systematic screening in 46.8%.
Retinopathy features present
The retinopathy features are described in Table 2 . Best-recorded visual acuity in the eye to be treated
The best-recorded visual acuity in the eye prior to treatment is shown in Table 3 , which reveals that 55.4%
of eyes to be treated had a best-recorded visual acuity of 6/9 or better, whilst 18.3% had a best-recorded visual acuity of 6/24 or worse. Where the visual acuity was less than 6/9 in the treated eye, 24.2% had some degree of cataract sufficient to cause a reduction in visual acuity. In the better eye, 70.0% of patients had a visual acuity of 6/9 or better, whilst 7.8% had a visual acuity of 6/24 or worse.
Waiting times to be seen in the ophthalmology out patient clinic and for the laser treatment
The waiting times to be seen in the ophthalmology clinic and for the laser treatment are shown in Table 4 . The grade of ophthalmologist performing panretinal photocoagulation is shown in Table 5 . A consultant ophthalmologist performed 35.6% of the photocoagulation.
Treatment given
In 41.2% of cases it was considered that the ophthalmologist intended to give the initial panretinal photocoagulation in one sitting. This was based upon the statement that the next appointment was for reassessment rather than specifically for further treatment. In 55.6% of cases it was intended to divide the initial treatment into more than one session, whilst in 3.2% of cases this information was not recorded. The spot sizes used for the panretinal photocoagulation are shown in Table 6 and the number of burns given at the first treatment is shown in Table 7 . For the group in which the intention was to give the initial panretinal photocoagulation treatment in one session (n = 117), the median number of burns given at the first session was 1146 (range 325-2686). 3.4% of eyes were given fewer than 500 burns, and 18.8% of eyes were given fewer than 800 burns.
A peri-or retrobulbar injection of anaesthetic was given in 6.9% of all patients undergOing panretinal photocoagulation, and in 5.7% of those who were given the initial treatment in one session. (19) the maculopathy was to be treated after the pametinal photocoagulation, whilst in 5.8% (5) there was no specific intention to treat the maculopathy.
For those in whom treatment of the maculopathy was to be after the pametinal photocoagulation, this was intended to be within 1 month of the pametinal photocoagulation in 10.5%, within 1-2 months in 31.6% and had not been decided in 57.9%. For those whose concurrent maculopathy was treated prior to pametinal photocoagulation, this was performed between 0.4 and 109 weeks before, with a median value of 18 weeks.
Follow-up
When the next appointment was specifically for further treatment (n = 158), the median interval was 2 weeks (range 1-11 weeks). Further treatment was to be given within 2 weeks in 60.3%, within 3-4 weeks in 28.8%, whilst 8.3% were to be brought back for further treatment after 5-6 weeks and 2.6% were to be brought back for further treatment after 6 weeks. When the next appointment was for reassessment rather than specifically for further treatment (n = 117), the median follow-up was 6 weeks (range 1-13 weeks). Reassessment was to be within 4 weeks in 30.2%, within 5-8 weeks in 55.1 %, whilst 14.7% were to be brought back for reassessment within 9-13 weeks.
Discussion
Patient characteristics
The sample had significantly more men than women. with younger-onset diabetes, whilst this was 2.0% for the older-onset group on insulin treatment, and 0.6% for the older-onset group not requiring insulin.17 In the UK, the incidence of sight-threatening retinopathy is thought to be 1.2_1.5%. 18 , 19 A comparison of the number of patients expected to undergo first panretinal photocoagulation treatment per annum in the UK and the numbers actually treated would suggest that there is a significant amount of sight-threatening retinopathy that is not currently being detected or treated.
Level of systematic screening
For those patients in whom proliferative retinopathy was present at the first outpatient clinic, the retinopathy was detected by systematic screening in 46.8%, and 28.7% of patients presented symptomatically. This large percentage of patients presenting symptomatically suggests that a significant amount of proliferative disease is not being detected or treated. The presence of the proliferative retinopathy was correctly diagnosed by the referrer in only 48.2% of cases compared with 80.8% for maculopathy, when the disease was noted at first presentation to the ophthalmology clinic.lO Moreover, 64.8% of maculopathy was detected by systematic screening, and 13.5% presented symptomatically. It would therefore appear that primary screening is less efficient at detecting proliferative retinopathy than maculopathy.
Since the detection of proliferative retinopathy relies on screening in the asymptomatic stage, the sensitivity of primary screening needs to improve.
Waiting times
While the median wait for treatment was only 2 weeks and 79.3% of patients were treated within 4 weeks of listing, 23.8% of patients with established disease still had to wait for more than 8 weeks to be seen in the Retinal area (square mm) outpatient clinic and the overall wait for treatment from referral was more than 12 weeks in 28.4%. Improvement of the waiting time to be seen in the ophthalmology clinic is indicated.
Treatment given at the first session
The Diabetic Retinopathy Study (DRS) protocol for panretinal photocoagulation recommended 800-1600 argon laser burns of 500 !Lm spot size extending to or beyond the vortex ampullae for eyes with high-risk characteristics? The ETDRS protocol for full scatter treatment was developed from this and recommended 1200-1600 argon laser burns of 500 !Lm spot size?O The ETDRS recommended that the treatment should be performed in two or more episodes, which were no more than 2 weeks apart, and that no more than 900 burns were to be applied in one session. An estimate of the area of retina ablated can be described using the standard formula of 'lTy2 multiplied by the number of burns (Fig. 2 ). Fig. 3 shows the results of this calculation for eyes with NVD and/ or NVD associated with vitreous haemorrhage (broadly equivalent to the 'high-risk characteristics' as defined by the DRS). To avoid complexity the type of lens used in treatment was not specified in the questionnaire. However, since the quadraspheric lens gives the greatest possible magnification of the commonly available contact lenses used in treatment (by a factor of 1.9), one can assume a range of magnification of the spot size of 1:1 to 1:1.9 when calculating the areas of treated retina.
For the group in whom the intention was to give the initial panretinal photocoagulation in one session (n = 117), the median retinal area treated was 98.2 mm2 
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Retinal area (square nun) Fig. 3 . Estimate of the area of retina ablated fo r eyes with new vessels on the disc and/or new vessels elsewhere associated with vitreous haemorrhage (broadly equivalent to 'high-risk characteristics' as defined by the DRS).
(range 6.7-682. For the subgroup with the equivalent of high-risk characteristics who were given their initial treatment in one session (n = 65), the corresponding figures were 60% and 80% respectively. If a spot magnification factor of 1.9 is taken for all cases, then 32.5% of eyes received less than the lower limit of the DRS protocol, and 40.2% of eyes received less than the lower limit of the ETDRS protocol. For the subgroup with the equivalent of high risk characteristics who were treated in one sitting these results were 30.8% and 38.5% respectively.
These smaller areas of retinal ablation would appear to result more from the spot size used than from the number of burns given, since only 18% of eyes that received the initial pametinal photocoagulation treatment in one session were given fewer than 800
burns. Hulbert and Vernon21 reported their practice of using 200 /Lm size burns in the initial treatment protocol, since this was often easier for the patient to tolerate and for the operator to deliver. Moreover, they found that this had beneficial effects on the ability of patients to retain driving fields. They found that between 3000 and 3500 burns induced regression in all but the most severe cases. whilst in 22% it was intended to treat the maculopathy after the panretinal photocoagulation. In the latter group, the mean age was 56.9 years (range 31-81 years), and these patients would not generally appear to fit into the category of young patients with aggressive disease in whom it may be best to perform panretinal photocoagulation first.
In conclusion, this audit has provided unique data concerning the processes of delivery of photocoagulation treatment for proliferative retinopathy throughout the United Kingdom. The issues that need to be addressed are:
1. The long waiting time for a clinic appointment for cases with established disease. This is an organisational issue that needs to be tackled locally.
2.
The large proportion of eyes presenting symptomatically (28.7%), which suggests poor screening procedures.
3. The possible initial undertreatment of some eyes with proliferative retinopathy. The follow-up study will show whether this is limited to the initial stages and whether outcome is affected.
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